Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key ...
Pediatric dosing expected to begin in Q4 2025Pivotal cohort expected to begin enrolling in Q1 2026BLA submission anticipated in early 2028Part A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback